CagriSema vs tirzepatide: Cost, Effectiveness, Side Effects Compared

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

Both options compared on this page are legitimate choices. The differences below are real but mostly modest. The bigger swing factors are usually outside the molecule itself.

Mechanism

CagriSema: CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide. The amylin pathway adds to GLP-1's appetite suppression through a separate mechanism, with the goal of greater total weight loss.

tirzepatide: Next-generation incretin agonists target combinations of GLP-1, GIP, and glucagon receptors with the goal of greater weight loss and metabolic benefit than GLP-1 alone.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

CagriSema: Phase 2 trials showed mean weight loss around 17% at 32 weeks. REDEFINE phase 3 reported 22.7% weight loss at 68 weeks.

tirzepatide: Most show 15-25% weight loss in late-phase trials.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: REDEFINE 1 (Garvey 2025) — 22 for CagriSema; Per-compound phase 2 or 3 trials for tirzepatide.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• nausea
• diarrhea
• vomiting
• decreased appetite

Important risks worth knowing for both:

• class-typical incretin risks pending long-term data
• incomplete long-term safety data pending phase 3 readouts

Cost

CagriSema: pricing varies. tirzepatide: pricing varies.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for CagriSema cost and tirzepatide cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between CagriSema and tirzepatide, either is a defensible choice in most cases.

Switching Between Them

Switching from CagriSema to tirzepatide (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

If you and your clinician are split between CagriSema and a comparator, you're probably in a "no wrong answer" zone. Pick the one with better access for you and reassess in 3 months.

Frequently Asked Questions

Related Reading

• CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.